260 related articles for article (PubMed ID: 10581998)
1. [Where to look for progress in antithrombotic treatments?].
Samama MM
Rev Prat; 1999 Oct; 49(15):1664-8. PubMed ID: 10581998
[TBL] [Abstract][Full Text] [Related]
2. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
5. The future of anticoagulation.
Hoppensteadt DA; Jeske W; Walenga J; Fareed J
Semin Respir Crit Care Med; 2008 Feb; 29(1):90-9. PubMed ID: 18302091
[TBL] [Abstract][Full Text] [Related]
6. Current trends in antithrombotic drug and device development.
Fareed J
Semin Thromb Hemost; 1996; 22 Suppl 1():3-8. PubMed ID: 8807721
[TBL] [Abstract][Full Text] [Related]
7. [New agents and challenges in the antithrombotic management of arterial diseases].
Udvardy M; Rák K
Orv Hetil; 1997 Jan; 138(2):59-65. PubMed ID: 9064617
[TBL] [Abstract][Full Text] [Related]
8. Factor Xa is a superior target to factor IIa for antithrombotic therapies.
Büller HR
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477
[No Abstract] [Full Text] [Related]
9. [Current and future antithrombotic therapies].
Uzan A
Ann Pharm Fr; 1996; 54(1):8-20. PubMed ID: 8702195
[TBL] [Abstract][Full Text] [Related]
10. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis and anticoagulation.
Hirsh J; Weitz JI
Semin Hematol; 1999 Oct; 36(4 Suppl 7):118-32. PubMed ID: 10595760
[TBL] [Abstract][Full Text] [Related]
12. [Peripheral arterial revascularization: which antithrombotic agents?].
Haulon S; Susen S; Koussa M; Jude B
Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1278-84. PubMed ID: 11794970
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic drugs for the secondary prevention of ischemic stroke.
Nenci GG; Goracci S
Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
[TBL] [Abstract][Full Text] [Related]
15. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?
Van de Werf F
Eur Heart J; 2009 Jul; 30(14):1695-702. PubMed ID: 19491132
[TBL] [Abstract][Full Text] [Related]
16. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic profile of the antithrombotic and bleeding actions of sulfated lactobionic acid amides.
Raake W; Klauser RJ; Meinetsberger E; Zeller P; Elling H
Semin Thromb Hemost; 1991; 17 Suppl 1():129-35. PubMed ID: 2068566
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cardiovascular events after acute coronary syndrome.
Wallentin L
Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
[TBL] [Abstract][Full Text] [Related]
19. Update on anticoagulant medications for the interventional radiologist.
Mehta RP; Johnson MS
J Vasc Interv Radiol; 2006 Apr; 17(4):597-612. PubMed ID: 16614141
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet agents and arterial thrombosis.
Billett HH
Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
